[
    {
        "file_name": "musclepharmcorp_20170208_10-ka_ex-10.38_9893581_ex-10.38_co-branding agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "(v)\nDuring the Term and during the sell-off period, MusclePharm shall make royalty payments in U.S. dollars for the\nrespective quarters ending on the last day of September, December, March and June (each, a “Royalty Period”) within\nthirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statement\nshowing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (by\ncountry and customer); (ii) the total number of units returned for which credit was given and the total dollar amount of\nsuch credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemized\nstatement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attached\nherto as Exhibit “B” and furnished to Lender whether or not any Licensed Products were sold during the Royalty\nPeriod.",
                "changed_text": "(v)\nDuring the Term and during the sell-off period, MusclePharm shall make royalty payments in U.S. dollars for the\nrespective quarters ending on the last day of September, December, March and June (each, a “Royalty Period”) within\nthirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statement\nshowing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (by\ncountry and customer); (ii) the total number of units returned for which credit was given and the total dollar amount of\nsuch credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemized\nstatement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attached\nherto as Exhibit “B” and furnished to Lender whether or not any Licensed Products were sold during the Royalty\nPeriod. MusclePharm shall make payments within sixty (60) days from the end of each quarterly period for the quarters ending on the last day of September and March.",
                "explanation": "This change introduces an in-text contradiction by specifying two different payment deadlines for royalty payments. The original text states that royalty payments should be made within thirty (30) days from the end of each quarterly period. The added text specifies that payments for the quarters ending in September and March can be made within sixty (60) days. This creates ambiguity and uncertainty regarding the actual payment terms, potentially leading to disputes.",
                "location": "Section 7(a)(v)"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "Exhibit “C”\n \nSection (1)\n \nGuaranteed Minimum Royalty during the initial Term:\n \nContract Year\n \nMinimum Royalty\n \nTiming of Payment\nOne\n \n$1,500,000\n \n$500,000 payment due on the following dates: July 23, 2013; October 1,\n2013; February 1, 2014\nTwo\n \n$2,000,000\n \n$666,666.66 payment due on the following dates: July 23, 2014; October\n1, 2014; February 1, 2015\nThree\n \n$2,500,000\n \n$833,333.33 payment due on the following dates: July 23, 2015; October\n1, 2015; February 1, 2016",
                "changed_text": "Exhibit “C”\n \nSection (1)\n \nGuaranteed Minimum Royalty during the initial Term:\n \nContract Year\n \nMinimum Royalty\n \nTiming of Payment\nOne\n \n$1,500,000\n \n$500,000 payment due on the following dates: July 23, 2013; October 1,\n2013; February 1, 2014. However, an additional payment of $250,000 is due on December 1, 2013.\nTwo\n \n$2,000,000\n \n$666,666.66 payment due on the following dates: July 23, 2014; October\n1, 2014; February 1, 2015\nThree\n \n$2,500,000\n \n$833,333.33 payment due on the following_dates: July 23, 2015; October\n1, 2015; February 1, 2016",
                "explanation": "This perturbation introduces conflicting payment terms by adding an additional payment deadline in Contract Year One. The original terms specify that $500,000 is due on July 23, 2013; October 1, 2013; and February 1, 2014. The added text indicates that an additional payment of $250,000 is due on December 1, 2013. This creates a discrepancy, as the original schedule doesn't include the December payment, causing confusion about the actual payment obligations.",
                "location": "Exhibit C, Section (1)"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "(c) In the event a shortfall in the amount of five percent (5%) or more is discovered, MusclePharm shall reimburse the AS Parties for the\ncost of the audit including any reasonable attorney’s fees incurred in connection therewith.",
                "changed_text": "(c) In the event a shortfall in the amount of five percent (5%) or more is discovered, MusclePharm shall reimburse the AS Parties for the\ncost of the audit including any reasonable attorney’s fees incurred in connection therewith. However, MusclePharm is only responsible for audit costs if the shortfall exceeds ten percent (10%).",
                "explanation": "Here, a contradiction is introduced regarding when MusclePharm must reimburse the AS Parties for audit costs. Originally, reimbursement is triggered by a shortfall of 5% or more. The added sentence raises the threshold to 10%, creating confusion about when MusclePharm's obligation to cover audit expenses arises.",
                "location": "Section 11(c)"
            }
        ]
    }
]